On December 8, Kevin Mahn of Hennion & Walsh appeared on CNBC’s ‘Closing Bell Overtime’ to discuss the potential for another bullish year, but with more volatility. Mahn noted the possibility of a hawkish cut from the Fed coming up on Wednesday, which he believes could bode well for the markets. He supported this with historical data and stated that since 1950, the Fed has cut interest rates on 23 different occasions when the S&P 500 was within 2% of its all-time high, as it is currently. In all 23 of those instances, the market moved higher over the next 12 months by an average of just under 14%. While acknowledging that this time could be different, Mahn expressed his view that the bull market will continue its run and notch its fourth consecutive year in 2026, though he expects many more bumps in the road along the way and much more short-term volatility than 2025.
Mahn also confirmed that if the Fed cuts interest rates this week, the Fed Fund’s target rate would move into a range of 3.5% to 3.75%. He noted that the Fed’s neutral rate is 3% (unless updated this week), which would leave only 50 basis points (or two 25 basis point cuts) remaining to reach neutral. He does not expect any cuts in Q1, noting that Q1 will include Chair Powell’s last two live FOMC meetings before he’s replaced as chair. Mahn suggested that they may only get one rate cut in 2026 and one in 2027. He then identified the big outstanding vote as the change in Fed Chair, which he noted could change everything. He expects the new Fed Chair to be more dovish, potentially resulting in a single 50 basis point cut when the new Chair takes over in the spring.
That being said, we’re here with a list of the 20 stocks that will double in 2026.
Our Methodology
We sifted through financial media reports and stock screeners to compile a list of the top stocks that will double in 2026 (with an upside potential between 100% and 200%). We then selected the 20 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q3 2025.
Note: All data was sourced on December 10.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
20 Stocks That Will Double in 2026
20. Bitfarms Ltd. (NASDAQ:BITF)
Average Upside Potential as of December 10: 104.08%
Number of Hedge Fund Holders: 25
Bitfarms Ltd. (NASDAQ:BITF) is one of the stocks that will double in 2026. On November 14, Alliance Global analyst Brian Kinstlinger raised the firm’s price target on Bitfarms to $6 from $2.50 and kept a Buy rating on the shares. This sentiment followed the company’s Q3 2025 earnings report. Kinstlinger believes that Bitfarms’ stock deserves a much higher multiple because the company is actively mitigating risks associated with timing, capital requirements, and future tenant demand. Bitfarms plans to transition most of its energy capacity to facilities dedicated to AI to generate long-term recurring revenue and yield very high margins, which could justify a higher valuation for the firm.
In its Q3 2025 earnings report, Bitfarms highlighted significant progress in transitioning from Bitcoin mining to becoming a leading North American HPC and AI infrastructure provider. However, this transition requires significant capital expenditure and operational changes, leading to inherent execution risks. A major uncertainty is the exact timeline for securing additional power capacity at key sites, specifically Panther Creek and Scrubgrass, which could delay project milestones. In the short term, winding down Bitcoin mining operations, starting with the sale of the Paso Pace facility (about 20% of their hash rate), will affect immediate cash flow until the HPC and AI projects become fully operational.
The company was able to make a total revenue of $83.66 million, which was an 86.52% increase as compared to the year-ago period, although this number missed Street expectations by $998.78K. However, Bitfarms generated a quarterly loss of $0.15 per share in Q3.
Bitfarms Ltd. (NASDAQ:BITF) operates integrated bitcoin data centers in Canada, the US, Paraguay, and Argentina. It primarily owns and operates data centers housing computers and sells computational power in multiple jurisdictions.
19. Solid Biosciences Inc. (NASDAQ:SLDB)
Average Upside Potential as of December 10: 155.10%
Number of Hedge Fund Holders: 25
Solid Biosciences Inc. (NASDAQ:SLDB) is one of the stocks that will double in 2026. On December 4, Needham analyst Gil Blum initiated coverage of Solid Biosciences with a Buy rating and $16 price target. Blum noted that the recent deaths of two non-ambulatory Duchenne muscular dystrophy patients who received Sarepta’s drug, Elevidys, raise concerns about the treatment’s benefit-risk profile. This safety issue may create a significant opportunity for competing gene therapies, specifically citing Solid Biosciences’ SGT-003. SGT-003 is intentionally designed to minimize liver toxicity while maintaining efficacy, and early trial results for SGT-003 have already shown robust microdystrophin expression.
In its Q3 2025 earnings report, Solid Biosciences disclosed that the company ended the quarter with $236.1 million in cash, cash equivalents, and available-for-sale securities, compared to $148.9 million as of December 31, 2024. This cash position is projected to fund the company’s operational runway into H1 2027. The net loss for Q3 was $45.8 million, up from $32.7 million in Q3 2024, primarily due to an increase in R&D expenses, which rose to $38.9 million from $27.3 million in Q3 2024, mainly driven by increased costs for the SGT-003 program.
Solid Biosciences’ SGT-003 Duchenne gene therapy trial (INSPIRE DUCHENNE) showed strong efficacy as of September 29, with all 10 participants evaluated at Day 90 achieving a mean microdystrophin expression of 58% and key DAPC restoration. The therapy was generally well tolerated with a steroid-only regimen, showing favorable cardiac safety signals and no DILI. The company has dosed 23 participants as of October 31, and plans to meet with the FDA in H1 2026 to discuss accelerated approval pathways after initiating the Phase 3 IMPACT DUCHENNE trial. The pipeline is also advancing, with new Phase 1b trials for FA (SGT-212) and CPVT (SGT-501) starting in Q4 2025.
Solid Biosciences Inc. (NASDAQ:SLDB) develops therapies for neuromuscular and cardiac diseases in the US. In addition, the company develops platform technologies, including capsid libraries, genetic regulators, immunomodulation technologies, manufacturing purity, and dual gene expression.
18. Gemini Space Station Inc. (NASDAQ:GEMI)
Average Upside Potential as of December 10: 124.47%
Number of Hedge Fund Holders: 27
Gemini Space Station Inc. (NASDAQ:GEMI) is one of the stocks that will double in 2026. On December 5, Goldman Sachs lowered the firm’s price target on Gemini to $17 from $19 and kept a Neutral rating on the shares.
Earlier on November 28, Evercore ISI lowered the firm’s price target on Gemini to $15 from $30 and maintained an Outperform rating on the shares. Evercore ISI revised its earnings forecast due to the then-current market conditions and the need to adjust its financial model forward from FY2026 to FY2027.
In Q3 2025, Gemini Space Station’s revenue for the quarter was $49.8 million, which represented a sequential increase of 52%, driven primarily by a 45% increase in trading volume and over 100% growth in credit card transaction volume. The quarter’s success was attributed to the strength of Gemini’s model, built on “trust, engagement, and liquidity. Transaction revenue reached $26.3 million, up 26% sequentially, supported by spot trading volumes of $16.4 billion (up 45% quarter-over-quarter).
On the product front, Gemini launched the Gemini Wallet, which is a self-custody smart wallet, and expanded multi-network support, including the launch of a Solana edition of the Gemini Credit Card and Solana Staking from Custody for institutions. For 2025, management reaffirmed its medium-term target for Monthly Transacting Users to grow at a 20% to 25% CAGR. They expect services revenue and interest income to reach $60 to $70 million for the full year and project sales and marketing expenses to total $45 to $60 million, reflecting targeted investment in growth.
Gemini Space Station Inc. (NASDAQ:GEMI) develops a crypto platform to buy, sell, and store crypto assets.
17. Evolus Inc. (NASDAQ:EOLS)
Average Upside Potential as of December 10: 175.42%
Number of Hedge Fund Holders: 28
Evolus Inc. (NASDAQ:EOLS) is one of the stocks that will double in 2026. On December 2, Mizuho lowered the firm’s price target on Evolus to $19 from $20, while keeping an Outperform rating on the shares. Mizuho lowered its estimates for Evolus’s products, Jeuveau and Evolysse, due to the recent decline in consumer sentiment. The firm now expects a higher probability of sustained inflationary pressure negatively impacting demand for elective injectable facial aesthetic procedures. Despite this headwind, Mizuho believes that Evolus still possesses long-term prospects.
Earlier in its Q3 2025 earnings report, Evolus achieved global net revenue of $69 million, which marked a 13% increase year-over-year. This growth was fueled by robust global demand for its flagship neurotoxin, Jeuveau, which generated $63.2 million in revenue, and early contributions from the new Hyaluronic Acid/HA filler, Evolysse, which brought in $5.7 million in the quarter. For the full year 2025, Evolus updated its total net revenue outlook, projecting figures between $295 and $305 million.
Evolus reinforced its market position and achieved a 14% market share in the US aesthetic neurotoxin market. The customer loyalty program is a key driver of engagement, having grown to over 1.3 million members, which represented a 34% year-on-year increase. The company also expanded its professional customer base, adding ~500 new purchasing accounts in Q3. Despite these positive indicators, the US aesthetic market faces ongoing challenges related to consumer spending, and the HA filler market, in particular, is down by double-digits, creating a difficult environment for Evolysse’s strong debut.
Evolus Inc. (NASDAQ:EOLS) is a performance beauty company that delivers products in the cash-pay aesthetic market in the US, Canada, Europe, and Australia.
16. Gogo Inc. (NASDAQ:GOGO)
Average Upside Potential as of December 10: 140.64%
Number of Hedge Fund Holders: 28
Gogo Inc. (NASDAQ:GOGO) is one of the stocks that will double in 2026. On December 9, William Blair downgraded Gogo to Market Perform from Outperform The company faces significant pressure from several fronts: intensifying competition due to Elon Musk’s Starlink rolling out service to commercial aircraft, Gogo’s currently elevated net debt position, and the expectation that Air-to-Ground net additions will likely remain strained for the next several quarters as the company completes its migration of customers from legacy Classic systems to the AVANCE platform.
In Q3 2025, Gogo announced that the company shipped a record 437 Air-to-Ground/ATG units in the quarter, signaling strong future installation activity. Gogo is making substantial progress with new product launches, including the 5G, HDX, and FDX technologies, which are designed to improve speed, consistency, and performance. This product momentum has translated into major contract wins, notably a significant deal with VistaJet to deploy HDX and FDX across its fleet.
Gogo is also well-positioned in the under-penetrated business jet market, where global flight levels are currently 30% above pre-COVID levels, sustaining strong demand for broadband connectivity. The company is seeing positive growth in its MilGov end market, where recent contract wins validate its multi-orbit, multi-band strategy. Furthermore, the transition to 5G is expected to deliver substantial Average Revenue Per User upside, as the 5G service offering is valued at twice that of a classic customer’s plan, enabling streaming and video applications on board.
The company recorded $223.59 million in total quarterly revenue, which grew by 122.41% year-over-year and beat estimates by $1.36 million. The loss per share for Q3 totaled $0.01,
Gogo Inc. (NASDAQ:GOGO), together with its subsidiaries, provides broadband connectivity services to the aviation industry in the US and internationally.
15. Cullinan Therapeutics Inc. (NASDAQ:CGEM)
Average Upside Potential as of December 10: 124.72%
Number of Hedge Fund Holders: 30
Cullinan Therapeutics Inc. (NASDAQ:CGEM) is one of the stocks that will double in 2026. On December 10, Clear Street raised the firm’s price target on Cullinan Therapeutics to $33 from $22 with a Buy rating on the shares. This sentiment was posted after the company announced updated data from the Phase 1 study of CLN-049.
Clear Street asserted that the clinical data for CLN-049 appear superior to that of most CD3 bispecific antibodies, confirming its differentiated biology and therapeutic potential. Consequently, the firm introduced a new market model for acute myeloid leukemia/AML specifically for CLN-049, projecting a launch in 2028 and forecasting risk-adjusted peak sales of $500 million by 2040.
Earlier in its Q3 2025 earnings call, the company reported a loss per share of $0.77. Cullinan Therapeutics’ net loss for Q3 was $50.6 million, which marked an increase from the $40.6 million net loss recorded in Q3 2024. The company maintains a robust financial standing, with a cash position of $475.5 million as of September 30. This provides the company with a projected financial runway extending into 2029.
The increase in net loss year-over-year reflects intensified investment in clinical programs. Furthermore, the company implemented a key strategic decision to focus resources on its most promising therapies. Cullinan discontinued its CLN-619 and CLN-617 programs, effectively narrowing its pipeline to high-conviction clinical stage programs. This move is intended to extend the company’s cash runway while concentrating investment on therapies that demonstrate the highest potential for impact in oncology and autoimmune diseases, particularly those leveraging its expertise in T cell engagers.
Cullinan Therapeutics Inc. (NASDAQ:CGEM) is a clinical-stage biopharmaceutical company that develops therapies for autoimmune diseases and cancer in the US.
14. Phreesia Inc. (NYSE:PHR)
Average Upside Potential as of December 10: 102.79%
Number of Hedge Fund Holders: 30
Phreesia Inc. (NYSE:PHR) is one of the stocks that will double in 2026. On December 10, Baird lowered the firm’s price target on Phreesia to $25 from $31 with an Outperform rating on the shares. This announcement was made after the firm updated its model to reflect the company’s latest guidance for 2026-2027.
Just a day prior, Phreesia released its FQ3 2026 earnings report, where the company announced a total revenue of $120.3 million, which marked a 13% increase year-over-year. Furthermore, Phreesia achieved positive net income for the second consecutive quarter, reporting $4.3 million for FQ3. The number of Average Healthcare Services Clients/AHSCs reached 4,520, an increase of 53% from the prior quarter, largely driven by the acquisition of AccessOne. Total revenue per AHSC also increased by 6% year-over-year, reaching $26,622.
Phreesia’s FY2026 revenue outlook was adjusted to a range of $479 to $481 million, which includes a more cautious approach to network solutions due to market fluidity and regulatory uncertainty surrounding direct-to-consumer advertising. FY2027 revenue outlook is expected to be in the range of $545 to $559 million. This 2027 revenue guidance anticipates mid-single-digit growth in AHSCs and double-digit growth in revenue per AHSC, with network solutions expected to be the fastest-growing segment, followed by payment processing and subscription services.
Phreesia Inc. (NYSE:PHR) provides an integrated SaaS-based software and payment platform for the healthcare industry in the US and Canada.
13. SunOpta Inc. (NASDAQ:STKL)
Average Upside Potential as of December 10: 104.08%
Number of Hedge Fund Holders: 30
SunOpta Inc. (NASDAQ:STKL) is one of the stocks that will double in 2026. On December 5, Freedom Capital analyst Raimzhan Bayterek initiated coverage of SunOpta with a Buy rating and $7.50 price target. Bayterek believes that the company is positioned to benefit from sustained consumer demand for healthier non-dairy products. Furthermore, SunOpta is entering a phase of margin expansion supported by greater operational efficiencies, optimized product mix, and stronger partnerships.
Earlier in Q3 2025, SunOpta reported a total revenue growth of 17% year-over-year, driven entirely by customer demand and totaling $205.41 million. Specifically, plant-based milk volumes increased at a high 10s rate in Q3, showcasing strong category growth. SunOpta services 8 of the top 10 coffee chains across North America, which benefits from the anticipated 20% growth in US coffee shop units over the next 5 years.
However, the company also experienced significant challenges, including temporary wastewater limitations at its Midlothian facility, which resulted in increased downtime and higher costs. Consequently, SunOpta had to delay some previously planned margin expansion initiatives to prioritize servicing the unexpected surge in demand. Despite the top-line volume growth, profitability was impacted, and gross margin decreased by 60 basis points to 12.4% compared to the prior year, reflecting increased costs due to operational inefficiencies stemming from the accelerated volume growth.
SunOpta Inc. (NASDAQ:STKL) manufactures and sells plant and fruit-based food and beverage products in the US, Canada, and internationally.
12. Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)
Average Upside Potential as of December 10: 120.39%
Number of Hedge Fund Holders: 32
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the stocks that will double in 2026. Earlier on November 18, BofA lowered the firm’s price target on Rocket Pharmaceuticals to $8 from $10 and kept a Buy rating on the shares following an updated cash position that was made after the company announced its Q3 2025 update.
In its Q3 2025 earnings report, Rocket Pharmaceuticals maintained a strong financial foundation, with cash, cash equivalents, and investments totaling ~$222.8 million as of the quarter end. This cash position is expected to provide an operational runway into Q2 2027, excluding potential future proceeds from a Priority Review Voucher/PRV that may be granted upon KRESLADI approval. The company also significantly reduced its net loss and operating expenses year-over-year. The net loss for Q3 was $50.3 million, or $0.45 per share (basic and diluted), a marked improvement from the Q3 2024 net loss of $66.7 million, or $0.71 per share. T
Rocket Pharmaceuticals achieved a critical milestone in its AAV cardiovascular gene therapy portfolio by successfully aligning with the FDA to lift the clinical hold on its pivotal Phase 2 trial of RP-A501 for Danon disease in under three months. Beyond Danon disease, engagement with the FDA is ongoing to align on the pivotal Phase 2 trial design for RP-A601 (for PKP2-ACM). Furthermore, Phase 1 trial start-up activities are underway for RP-A701 (for BAG3-DCM), with the first-in-human multi-center, dose-escalation study details found under NCT identifier NCT07137338. In the lentiviral portfolio, the BLA resubmission for KRESLADI (marnetegragene autotemcel; marne-cel) for severe LAD-I was accepted by the FDA, with a PDUFA target action date set for March 28, 2026.
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT), together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the US.
11. Burford Capital Limited (NYSE:BUR)
Average Upside Potential as of December 10: 111.23%
Number of Hedge Fund Holders: 33
Burford Capital Limited (NYSE:BUR) is one of the stocks that will double in 2026. Earlier on November 11, B. Riley analyst Timothy D’Agostino lowered the firm’s price target on Burford Capital to $18 from $20 with a Buy rating on the shares. This sentiment followed the company’s Q3 2025 earnings report. D’Agostino believes that the recent decline in the stock price offers an attractive entry point for investors.
In its Q3 report, Burford Capital announced achieving a significant increase in definitive commitments, up more than 50%, and reported overall portfolio growth of 15% year-to-date. Furthermore, Q3 saw a 61% increase in deployments, indicating robust current business activity. Burford remains on track to achieve its long-term strategic goal of doubling the business by 2030, which corresponds to a 20% annualized growth rate.
Burford’s investment strategy is focused on diversification across various geographies, case types, durations, and risk profiles, which helps mitigate potential losses. The company recorded $69.80 million in revenue, although it also faced a loss per share of $0.09. Looking ahead, management anticipates continued momentum in realizations, with more trials and hearings scheduled for the next 12 months than were scheduled a year ago.
Burford Capital Limited (NYSE:BUR) provides legal finance products and services worldwide. The company operates in two segments: Principal Finance and Asset Management & Other Services.
10. Kura Oncology Inc. (NASDAQ:KURA)
Average Upside Potential as of December 10: 160.71%
Number of Hedge Fund Holders: 34
Kura Oncology Inc. (NASDAQ:KURA) is one of the stocks that will double in 2026. On November 24, Barclays analyst Etzer Darout raised the firm’s price target on Kura Oncology to $28 from $11 and maintained an Overweight rating on the shares. This decision was made as Barclays saw potential in the company’s ziftomenib approval.
This approval came earlier, on November 18, when Kura Oncology and Kyowa Kirin Co. Ltd. announced that the US FDA granted full approval to KOMZIFTI (ziftomenib) for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia/AML harboring a susceptible NPM1 mutation who lack satisfactory alternative treatment options. KOMZIFTI is the first and only once-daily, oral menin inhibitor approved for this devastating blood cancer, which affects ~30% of AML cases and often leads to early relapse.
Kura Oncology is prepared to launch the new medicine immediately. The approval is supported by data from the pivotal KOMET-001 trial, which evaluated KOMZIFTI in 112 R/R NPM1-mutated AML patients. The trial demonstrated compelling efficacy, with a combined rate of complete remission/CR plus CR with partial hematologic recovery/CRh of 21.4%. A key advantage highlighted by the data is KOMZIFTI’s favorable safety profile: it was approved with no Boxed Warning related to QTc prolongation or Torsades de Pointes, easing co-administration with other medications. The most common adverse reactions included various lab abnormalities (e.g., increased AST/ALT, decreased potassium, decreased albumin) and infections.
Kura Oncology Inc. (NASDAQ:KURA) is a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer.
9. MBX Biosciences Inc. (NASDAQ:MBX)
Average Upside Potential as of December 10: 113.39%
Number of Hedge Fund Holders: 34
MBX Biosciences Inc. (NASDAQ:MBX) is one of the stocks that will double in 2026. On December 4, Goldman Sachs initiated coverage of MBX Biosciences with a Sell rating and $18 price target. The key challenge for the company over the next year is demonstrating the validity of its platform beyond its lead drug, canvuparatide. The next major data catalyst will be the Phase 2a Post-Bariatric Hypoglycemia results, expected in Q2 2026. However, the firm suggested that these data may fall short of demonstrating meaningful differentiation, potentially resulting in a difficult risk/benefit profile. While long-term extension data for canvuparatide appear relatively de-risked, and early-stage obesity data in Q4 2026 could offer platform validation, both of these programs remain too early to support.
In other news, MBX Biosciences reported its Q3 2025 earnings report earlier, where the company highlighted positive topline results from the Phase 2 Avail trial of once-weekly canvuparatide in hypoparathyroidism/HP, the completion of an upsized public offering that raised ~$200 million in gross proceeds, and a strong financial position with $391.7 million in cash, cash equivalents, and marketable securities as of September 30, 2025. This cash runway is expected to support operations into 2029.
Q3 was marked by significant execution, including the positive topline results for canvuparatide, which the company believes has the potential to be a best-in-class treatment for the multibillion-dollar HP market. MBX is currently preparing for meetings with US and EU regulatory agencies and planning for the initiation of its Phase 3 trial and future commercialization. In the Obesity program, the first participant was dosed in the Phase 1 trial of MBX 4291, a PEP glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide/GIP co-agonist prodrug. For Post-bariatric Hypoglycemia/PBH, the company dosed the first patient in the Phase 2a STEADI trial of imapextide (MBX 1416).
MBX Biosciences Inc. (NASDAQ:MBX) is a clinical-stage biopharmaceutical company that discovers and develops precision peptide therapies for the treatment of endocrine and metabolic disorders.
8. Day One Biopharmaceuticals Inc. (NASDAQ:DAWN)
Average Upside Potential as of December 10: 164.39%
Number of Hedge Fund Holders: 36
Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) is one of the stocks that will double in 2026. On November 24, JonesTrading analyst Soumit Roy maintained a bullish stance on the company, with a Buy rating.
On the same day, Day One Biopharmaceuticals also announced 3-year follow-up results from the pivotal Phase 2 FIREFLY-1 trial of OJEMDA (tovorafenib). This updated data, derived from the ongoing FIREFLY-1 trial (Arm 1) with a median study duration of 40.6 months (data cutoff June 6 this year), expands on the previously reported clinically meaningful results.
Tovorafenib is a Type II RAF kinase inhibitor approved by the US FDA for treating pediatric patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma/pLGG harboring a BRAF fusion or rearrangement. The approval was granted under accelerated approval based on the response rate and duration of response.
No new safety signals were identified in this updated three-year analysis. Grade 3 or higher adverse events most commonly reported included decreased growth velocity, anemia, increased blood creatine phosphokinase, maculopapular rash, and increased alanine aminotransferase.
Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) is a commercial-stage company that advances class medicines for childhood and adult diseases with equal intensity in the US.
7. Gossamer Bio Inc. (NASDAQ:GOSS)
Average Upside Potential as of December 10: 157.88%
Number of Hedge Fund Holders: 36
Gossamer Bio Inc. (NASDAQ:GOSS) is one of the stocks that will double in 2026. On December 9, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Gossamer Bio, with a price target of $15.
Earlier on November 10, Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Gossamer Bio to $12 from $9 with an Outperform rating on the shares following the company’s announcement of its Q3 2025 earnings results.
Oppenheimer is highly confident about the upcoming topline readout for the PROSERA trial in February 2026. This confidence is supported by the baseline characteristics of the PROSERA study population and the positive results previously reported in the Phase 2 TORREY data, which collectively increase the probability of PROSERA achieving its primary endpoint of statistically significant improvement in the 6-Minute Walk Distance. Furthermore, the company has successfully activated the first clinical site for the Phase 3 SERANATA/PH-ILD trial, with results from this pivotal study currently anticipated in 2027.
In other news, Gossamer Bio reported a revenue of $13.3 million in Q3 2025 earlier, which includes $9.2 million of cost reimbursement revenue from its global collaboration with the Chiesi Group, significantly surpassing the estimated $6.33 million. However, the net loss for the quarter was $48.2 million, or a $0.21 basic net loss per share, which was below the estimated loss of $0.18 per share. This was a wider loss compared to the net loss of $30.8 million, or $0.14 per share, recorded in Q3 2024.
Gossamer Bio Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company that develops and commercializes seralutinib for the treatment of pulmonary arterial hypertension/PAH in the US.
6. Viking Therapeutics Inc. (NASDAQ:VKTX)
Average Upside Potential as of December 10: 167.79%
Number of Hedge Fund Holders: 37
Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the stocks that will double in 2026. Earlier on November 12, Canaccord raised the firm’s price target on Viking Therapeutics to $107 from $106 with a Buy rating on the shares. Canaccord considers Viking Therapeutics’ shares to be significantly undervalued, especially when factoring in the more advanced stage of the company’s obesity pipeline. Canaccord currently regards Viking Therapeutics as an extremely attractive asset within the obesity therapeutic area and recognizes it as the leading biotech company in obesity clinical development.
In Q3 2025, Viking Therapeutics highlighted significant progress in its obesity pipeline, particularly for the dual GLP-1/GIP receptor agonist, VK2735, but also reported a substantial increase in net loss driven by clinical trial expenses. The company reported an increase in its net loss for Q3, which totaled $90.8 million or $0.81 per share, compared to a net loss of $24.9 million or $0.22 per share in Q3 2024. This increase was primarily driven by a sharp rise in R&D expenses, which soared to $90 million for Q3 2025, up from $22.8 million in the same quarter of 2024.
Viking Therapeutics also announced positive top-line results from a Phase 2 clinical trial of the oral tablet formulation of VK2735, which showed statistically significant reductions in body weight compared with placebo. The company’s pivotal Phase 3 VANQUISH Obesity program for the subcutaneous formulation is advancing well. Furthermore, Viking is advancing a novel maintenance dosing study for VK2735, which explores various dosing regimens to maintain weight loss and potentially enhance long-term treatment adherence.
Viking Therapeutics Inc. (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company that develops novel therapies for metabolic and endocrine disorders.
5. Evolent Health Inc. (NYSE:EVH)
Average Upside Potential as of December 10: 151.29%
Number of Hedge Fund Holders: 38
Evolent Health Inc. (NYSE:EVH) is one of the stocks that will double in 2026. On November 21, Citi lowered the firm’s price target on Evolent Health to $9.50 from $11.50 while maintaining a Buy rating on the shares.
Earlier on November 14, Canaccord also lowered the firm’s price target on Evolent Health to $9 from $16 while keeping a Buy rating on the shares. Canaccord lowered its target valuation by removing the premium previously assigned to the stock. This adjustment is due to the increased near-term uncertainty surrounding Evolent Health’s shares, which are currently in limbo. Furthermore, ongoing ambiguity regarding Medicare Advantage and Medicaid membership changes is also holding the stock hostage in the near term.
In its Q3 2025 earnings report, Evolent Health announced delivering $480 million in Q3 revenue, which represented an 8% sequential growth and was at the top of its guidance range. For the full year 2025, Evolent Health maintained its revenue guidance to be between $1.87 and $1.88 billion. The company ended the quarter with $116.7 million in cash and equivalents.
Looking ahead to 2026, Evolent Health secured ~$2.5 billion in revenue under contract. This includes two new revenue arrangements expected to add more than $550 million in new revenue for 2026. The new contracts operate under an enhanced performance suite featuring a narrower corridor model with prevalence and case mix adjustments, which is now the standard structure for new and existing business.
Evolent Health Inc. (NYSE:EVH), through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the US.
4. Aurora Innovation Inc. (NASDAQ:AUR)
Average Upside Potential as of December 10: 151.29%
Number of Hedge Fund Holders: 38
Aurora Innovation Inc. (NASDAQ:AUR) is one of the stocks that will double in 2026. On December 9, Itay Michaeli from TD Cowen maintained a Hold rating on Aurora Innovation, with a price target of $5.50.
In other news, on December 8, Aurora Innovation announced a commercial agreement with Detmar Logistics, which is a primary provider of dry bulk and frac sand logistics solutions. Under this agreement, Aurora will deploy its autonomous trucks to transport proppants (frac sand) around the clock for one of the world’s largest multinational oil and gas companies in the Permian Basin.
This deployment is highly significant as it marks the first time frac sand will be hauled autonomously on public roads and highways in the Permian Basin. The autonomous operations will begin early next year with supervised operations between Detmar’s facility in Midland, Texas, and Capital Sand’s mining site in Monahans, Texas.
Once Aurora deploys its second fleet of driverless trucks, expected in Q2 2026, these trips for Detmar will transition to fully driverless operations without anyone on board. This route combines high-speed driving on Interstate 20 with local and private roads and establishes one of Aurora’s initial routes between customer sites. Under the initial contract, Detmar is committed to using 30 Aurora Driver-powered trucks in 2026, with each unit hauling sand for over 20 hours a day.
Earlier on November 26, Goldman Sachs lowered its price target on Aurora Innovation to $4 from $6 with a Neutral rating on the shares.
Aurora Innovation Inc. (NASDAQ:AUR) operates as a self-driving technology company in the US. It develops Aurora Driver, which is a platform that brings self-driving hardware, software, and data services together to adapt and interoperate with various vehicle types and applications.
3. ORIC Pharmaceuticals Inc. (NASDAQ:ORIC)
Average Upside Potential as of December 10: 115.00%
Number of Hedge Fund Holders: 39
ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) is one of the stocks that will double in 2026. On December 8, Wells Fargo raised the firm’s price target on Oric Pharmaceuticals to $25 from $19 and maintained an Overweight rating on the shares. Although enozertinib has previously been overshadowed by ORIC-944, the intriguing data presented at ESMO Asia is significant enough for Wells Fargo to believe that investors should begin to assign greater value to this asset. The firm thinks that the company’s shares should experience an upward trend in trading.
Earlier in Q3 2025, ORIC Pharmaceuticals highlighted significant progress toward initiating potential Phase 3 trials for its two lead candidates in 2026 and confirmed a strong financial position. ORIC’s cash, cash equivalents, and investments totaled ~$413.0 million as of September 30. This amount includes $125 million from a private placement financing in May 2025 and $117.6 million in net proceeds raised year-to-date under its ATM program.
This capital is expected to fund the company’s operating plan into the second half of 2028 and beyond the anticipated primary endpoint readouts from the first Phase 3 trials for both ORIC-944 and enozertinib. However, the company also recorded a loss per share of $0.33.
ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) is a clinical-stage biopharmaceutical company that discovers and develops therapies to counter the resistance mechanisms of cancers in the US.
2. Strategy Inc. (NASDAQ:MSTR)
Average Upside Potential as of December 10: 159.69%
Number of Hedge Fund Holders: 43
Strategy Inc. (NASDAQ:MSTR) is one of the stocks that will double in 2026. On December 8, Bernstein lowered the firm’s price target on Strategy to $450 from $600 with an Outperform rating on the shares. Bernstein maintains its conviction that market concerns regarding Strategy’s financial stability are overstated. The firm believes that Strategy is rapidly evolving into a Bitcoin-reserved financial operating business, focusing on delivering fixed income yield and savings products directly to investors.
In Q3 2025, Strategy highlighted substantial growth driven by its dominant Bitcoin treasury strategy. The company reported $3.9 billion in operating income, $2.8 billion in net income, and EPS of $8.43. EPS, however, missed Street estimates by $1.25. The company also generated $128.69 million in quarterly revenue, which was a 10.87% rise year-over-year, and beat expectations by $11.76 million.
Strategy maintained an optimistic outlook and reaffirmed its full-year 2025 guidance with an operating income target of $34 billion, a net income target of $24 billion, and an EPS target of $80. However, the company’s heavy reliance on Bitcoin introduces significant volatility and risk, and the high leverage inherent in its amplification strategy could pose risks if the Bitcoin market deteriorates.
Strategy Inc. (NASDAQ:MSTR), together with its subsidiaries, operates as a bitcoin treasury company in the US, Europe, the Middle East, Africa, and internationally.
1. UniQure (NASDAQ:QURE)
Average Upside Potential as of December 10: 163.16%
Number of Hedge Fund Holders: 59
UniQure (NASDAQ:QURE) is one of the stocks that will double in 2026. On December 9, Mizuho analyst Uy Ear lowered the firm’s price target on uniQure to $33 from $60, while keeping an Outperform rating on the shares. The firm adjusted its financial model for AMT-130 after the company announced that the FDA communicated concerns that the current data submitted from the Phase I/II studies for Huntington’s disease are presently unlikely to serve as the primary evidence needed to support a BLA. Consequently, Mizuho reduced its view of AMT-130’s probability of success and delayed its expected launch by 1 year.
In other news, earlier in its Q3 2025 earnings report, UniQure detailed promising clinical data for its lead gene therapy candidate, AMT-130, alongside new regulatory challenges. The company reported $3.7 million in revenue, an increase from $2.3 million in Q3 2024. However, financial expenses rose, with R&D expenses reaching $34.4 million (up from $30.6 million in Q3 2024) and SG&A expenses totaling $19.4 million (up from $11.6 million in Q3 2024). The increase in R&D was primarily driven by costs associated with preparing BLA for AMT-130, while the rise in SG&A was due to increased employee-related expenses and professional fees.
UniQure also announced positive top-line data from its pivotal Phase I/II study of AMT-130 for Huntington’s disease, showing a statistically significant slowing of disease progression over 3 years. Specifically, the high dose demonstrated a 75% slowing of disease progression, meeting the study’s primary endpoint. The therapy also showed a 60% slowing of disease progression in the key secondary endpoint of total functional capacity at 3 years.
UniQure (NASDAQ:QURE) develops treatments for patients suffering from rare and other devastating diseases in the US.
While we acknowledge the potential of QURE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than QURE and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
